/VYGR
VYGR Stock - Voyager Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$4.00-2.91%
$0.12 (-2.91%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.45
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+150.0%upside
Target: $10.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VYGR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.96 – $4.04
TARGET (TP)$10.00
STOP LOSS$3.68
RISK/REWARD1:18.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.24
52W High$6.27
52W Low$2.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $80.00M | $250.01M | $40.91M | $37.41M | $171.13M |
| Gross Profit | $80.00M | $157.84M | $-14,857,000 | $-36,372,000 | $62.38M |
| Gross Margin | 100.0% | 63.1% | -36.3% | -97.2% | 36.4% |
| Operating Income | $-83,287,000 | $122.01M | $-50,837,000 | $-73,618,000 | $27.38M |
| Net Income | $-65,002,000 | $132.33M | $-46,408,000 | $-71,197,000 | $36.74M |
| Net Margin | -81.3% | 52.9% | -113.4% | -190.3% | 21.5% |
| EPS | $-1.13 | $3.08 | $-1.21 | $-1.75 | $0.99 |
Company Overview
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 322.2% Upside
Now
$11
Low
$17
Average
$30
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 10th 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| December 2nd 2024 | Citigroup | Initiation | Buy | $12 |
| November 29th 2024 | Wedbush | Resumed | Outperform | $11← $7 |
| October 16th 2024 | Leerink Partners | Initiation | Outperform | $15 |
| March 26th 2024 | Guggenheim | Initiation | Buy | $22 |
| March 19th 2024 | H.C. Wainwright | Initiation | Buy | $30 |
| March 7th 2024 | Citigroup | Initiation | Buy | $16 |
| January 2nd 2024 | Wells Fargo | Upgrade | Overweight | $14 |
| May 10th 2023 | Truist | Initiation | Buy | $18 |
| March 10th 2023 | Oppenheimer | Initiation | Outperform | $14 |
Earnings History & Surprises
VYGRBeat Rate
61%
Last 18 quarters
Avg Surprise
+53.6%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$-0.47
Q4 2025
EPS Surprise History
Q1 24
+531.0%
$1.25vs$-0.29
Q2 24
+54.5%
$-0.20vs$-0.44
Q3 24
+52.6%
$-0.18vs$-0.38
Q4 24
+64.4%
$-0.16vs$-0.45
Q1 25
-68.6%
$-0.59vs$-0.35
Q2 25
-51.4%
$-0.53vs$-0.35
Q3 25
-18.7%
$-0.57vs$-0.48
Q4 25
+11.3%
$-0.47vs$-0.53
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $-0.54 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.53 | $-0.47 | +11.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.48 | $-0.57 | -18.7% | ✗ MISS |
Q2 2025 | May 6, 2025 | $-0.35 | $-0.53 | -51.4% | ✗ MISS |
Q1 2025 | Mar 11, 2025 | $-0.35 | $-0.59 | -68.6% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-0.45 | $-0.16 | +64.4% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.38 | $-0.18 | +52.6% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.44 | $-0.20 | +54.5% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.29 | $1.25 | +531.0% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.58 | $-0.59 | -1.7% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.59 | $-0.51 | +13.6% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $0.77 | $2.94 | +281.8% | ✓ BEAT |
Q1 2023 | Mar 7, 2023 | $-0.57 | $-0.61 | -7.0% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.32 | $0.45 | +240.6% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.56 | $-0.50 | +10.7% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.14 | $-0.56 | -300.0% | ✗ MISS |
Q1 2022 | Mar 8, 2022 | $-0.32 | $0.15 | +146.9% | ✓ BEAT |
Q4 2021 | Nov 2, 2021 | $-0.75 | $-0.67 | +10.7% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.75 | $-0.80 | -6.7% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on Voyager Therapeutics, Lowers Price Target to $25
➖ NeutralBenzinga•Nov 12, 2025, 06:44 PM
Voyager Therapeutics Files For Mixed Shelf Offering Of Up To $400M
➖ NeutralBenzinga•Nov 10, 2025, 09:10 PM
Transition Bio Collaborates With Voyager To Advance Small Molecules Targeting TDP-43 In ALS And Frontotemporal Dementia
📈 PositiveBenzinga•Nov 10, 2025, 01:18 PM
Voyager Therapeutics Q3 EPS $(0.47) Beats $(0.51) Estimate, Sales $13.365M Beat $7.858M Estimate
📈 PositiveBenzinga•Nov 10, 2025, 01:16 PM
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target
📈 PositiveBenzinga•Sep 15, 2025, 11:11 AM
Frequently Asked Questions about VYGR
What is VYGR's current stock price?
Voyager Therapeutics, Inc. (VYGR) is currently trading at $4.00 per share. The stock has moved -2.91% today.
What is the analyst price target for VYGR?
The average analyst price target for VYGR is $10.00, based on 1 analyst.
What sector is Voyager Therapeutics, Inc. in?
Voyager Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VYGR's market cap?
Voyager Therapeutics, Inc. has a market capitalization of $0.22 billion, making it a small-cap company.
Does VYGR pay dividends?
No, Voyager Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHV
Achieve Life Sciences, Inc.
$4.32
Mkt Cap: $0.2B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
AVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
HUMA
Humacyte, Inc.
$1.11
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
SGMT
Sagimet Biosciences Inc.
$6.28
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VNDA
Vanda Pharmaceuticals Inc.
$6.75
Mkt Cap: $0.4B
Explore stocks similar to VYGR for comparison